S225
Factors, Recognition, Prevention and Treatment of Bisphosphonate-induced Osteonecrosis of the Jaws

Thursday, October 10, 2013
9:30 AM-11:30 AM
Location

W224E (Orange County Convention Center)

TicketedThis is a Ticketed Session
Handouts
  • S225.pdf (36.8 MB)
    • Speaker:

    Robert E. Marx DDS
    Miami, FL, USA


    Co-Speaker:

    Vishtasb Broumand DMD, MD
    Miami, FL, USA


    CDE/CME Offered: CDE/CME
    Synopsis

    Many believe that both oral and intravenous bisphosphonates have toxic effects on osteoclasts resulting in bone renewal suppression. Today, some believe a relatively new drug, Denosumab, works in the same fashion. Some professionals have opined that these drugs have led to jaw necrosis. Preventive measures and treatment protocols are in place that can reduce risk and more completely manage patients. Preventative measures and treatment protocols are in place that can reduce risk and more completely manage patients.

    Learning Objectives
    1. Explain bone remodeling/renewal and its dependance on osteoclast function and stimulation of the osteoblasts;
    2. Prevent osteonecrosis from developing in many of their patients. Teach fellow OMSs and other dental specialists these effective protocols; and
    3. Describe preventive care to reduce the risks of osteonecrosis from bisphosphonates and RANKL ligand inhibitors, as well as ways to effectively treat patients who develop osteonecrosis.

    Audio File Recorded Presentation
    » Back to: Clinical Courses